Invest in the Fight Against Candida auris and Drug-Resistant Superbugs

Candida auris, a WHO critical priority pathogen, has seen U.S. cases surge from 51 in 2016 to 4,514 in 2023. This deadly drug-resistant fungal infection has 30-60% mortality rates and threatens global health. Clue Genetics is developing solutions using the world's largest private fungal genomics platform.

View Investment Opportunity Learn More

NSF SBIR Grant: $275,000

50,000+ Fungal Strains

11 Strains Effective vs. Candida auris

The Global Health Crisis

Drug-resistant fungal infections and agricultural pathogens pose existential threats to human health and food security

0 +

Deaths Annually

Drug-resistant fungal infections kill over 1.5 million people worldwide each year

Candida auris Explosion

U.S. clinical cases of Candida auris (C. auris) surged 88x in just 7 years. This WHO critical priority pathogen has 30-60% mortality rates and is often resistant to all major antifungal drug classes.

51 cases (2016) 4,514 cases (2023)

$ 0 B+

Agricultural Losses

Fungal crop pathogens cause $220+ billion in annual losses globally, threatening food security

Our Solution: A Proven Natural Products Platform

The world's largest private fungal strain library combined with cutting-edge genomics

50,000+ Living Fungal Strains

Nearly Impossible to Replicate

Clue Genetics owns one of the world's largest private fungal strain libraries—over 50,000 diverse living strains collected from 40+ countries before the 1993 Convention on Biological Diversity, giving us a unique and irreplaceable resource.

Bioassay-Guided Screening

Identify biologically active compounds effective against drug-resistant pathogens

Genomics Analysis

Sequence and analyze fungal genomes to identify biosynthetic gene clusters

IP Development

Generate intellectual property for licensing to pharmaceutical and agritech companies

Unmatched Competitive Advantages

Pre-CBD Collection

Assembled before 1993 Convention on Biological Diversity restrictions—the collection would be almost impossible to recapitulate today

Living Strains

Physical cultures enable compound production and optimization—not just sequence data

Proven Hits

400+ bioactive molecules already identified from decades of screening

Experienced Team

100+ years combined experience in genomics, mycology, and natural products commercialization

Validated Technology Platform

NSF-funded success with proven results against critical pathogens

NSF SBIR Phase I

$275,000 Grant Awarded

April 2024 - Funded work successfully completed

Priority Antifungal Strains

Effective against drug-resistant Candida auris (C. auris) with low mammalian toxicity

Agricultural Biocontrol Strains

Active against major crop pathogens: late blight, anthracnose, gray mold, target spot, sudden death syndrome

3,145

Strains DNA-Fingerprinted

Catalogued, identifying 866 distinct species including 565 novel or understudied taxa

100+

Genomes Sequenced

Fungal genome sequencing platform validated with full analysis identifying biosynthetic gene clusters

Massive Market Opportunity

Therapeutic Drug Market

$ 1 Trillion+

Projected market by early 2030s due to age- and lifestyle-related diseases

Agricultural Solutions

$ 220 Billion+

Annual crop losses creating demand for new antifungal biopesticides

Multi-Market Revenue Strategy

Clear path to returns through strategic licensing and partnerships

0-12 Months

Agrichemical Sector Licensing

License validated antifungal strains and extracts to agricultural biotech companies for biopesticide development. Demonstrated efficacy against major crop pathogens positions us for partnerships with major players such as BASF, Bayer, Corteva, Syngenta, and specialty biocontrol companies.

1-2 Years

Pharmaceutical & Cosmetics IP Licensing

Advance Candida auris-active compounds toward clinical development through pharma partnerships. License specialized compounds to leaders in the cosmetics and industrial enzyme markets.

2+ Years

Platform Licensing & Strategic Exit

Build recurring revenue through ongoing strain library access agreements and biosynthetic gene cluster IP. Position for acquisition by major agricultural, pharmaceutical, or specialty chemical companies seeking natural products pipelines.

Recent Progress & Milestones

NSF Phase I Success

April 2024: Awarded $275,000 to build metabologenomics platform. Successfully characterized 3,145 strains, identified 11 priority antifungal candidates against Candida auris, and completed dereplication studies confirming novel chemical scaffolds.

Expanded Market Validation

2024: Third party partnership screening demonstrated 28% hit rate against agricultural pathogens, validating dual-market (healthcare + agriculture) commercialization strategy.

First Revenues Established

Licensing and collaboration agreements executed with third parties, generating initial revenue and validating commercial interest.

Genomics Infrastructure

Over 100 fungal genomes fully sequenced with bioinformatics pipeline identifying thousands of biosynthetic gene clusters—establishing foundation for future IP generation and synthetic biology partnerships.

World-Class Leadership Team

100+ years of combined experience in genomics, natural products, and biotech commercialization

Dr. Cedric Pearce, PhD

President & Co-Founder

Former Big Pharma (Bristol-Myers, American Cyanamid), 20+ years in natural products discovery and biotech startups. Past President, American Society of Pharmacognosy. Holds numerous patents and 200+ publications.

200+ Publications Past ASP President

Dr. Peter Repetti, PhD

Chief Scientific Officer

UC Berkeley PhD in Plant & Microbial Biology. 20+ years leading R&D at Mendel Biotechnology and Koch Agronomic Services. 29 patents. Expertise in genomics, plant-pathogen interactions, and agricultural applications.

29 Patents UC Berkeley

Dr. Oliver Ratcliffe

Executive Chairman & Co-Founder

Cambridge MBA with strong science and business background. Serial entrepreneur with previous successful genomics company exit. Decades of experience building biotech businesses and securing capital.

Previous Exit Cambridge MBA

Join Us in Fighting Drug-Resistant Infections

Investment opportunity now available through StartEngine equity crowdfunding

NSF-Validated Technology

50,000+ Irreplaceable Strains

11 Strains Effective vs. Candida auris

Proven Leadership Team

Invest Now on StartEngine

This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.